CRVS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
19.3M
+29.7%
14.9M
+21.8%
12.2M
+15.6%
10.6M
+3.0%
10.3M
R&D
16.0M
+42.9%
11.2M
+12.4%
9.9M
+17.6%
8.5M
+7.4%
7.9M
SG&A
3.3M
-10.0%
3.7M
+62.5%
2.3M
+7.6%
2.1M
-11.3%
2.4M
Operating Income
-19297000
-29.7%
-14877000
-21.8%
-12217000
-15.6%
-10572000
-3.0%
-10260000
EBITDA
-19263000
-29.7%
-14848000
-21.8%
-12191000
-15.6%
-10544000
-3.1%
-10231000
Net Income
-17959000
-31.2%
-13692000
-11.1%
-12321000
-21.3%
-10157000
-27.0%
-7998000
EPS (Basic)
$-0.19
-26.7%
$-0.15
+0.0%
$-0.15
-25.0%
$-0.12
-20.0%
$-0.10
EPS (Diluted)
$-0.19
-26.7%
$-0.15
+0.0%
$-0.15
-25.0%
$-0.12
-20.0%
$-0.10
Shares (Diluted)
92.4M
+2.6%
90.0M
+8.2%
83.2M
+0.4%
82.8M
+6.5%
77.8M
Corvus Pharmaceuticals (CRVS) โ€” Financials